Published Date: 10 Mar 2023
Over the past decade, frozen embryo transfer (FET) has been increasingly used by infertility clinics today. Few years ago...
Read Full NewsConaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.
The adaptive PRImus-AD phase 2a trial will evaluate the safety and efficacy of PRI-002, a novel investigational agent, in patients with mild cognitive impairment or mild Alzheimer disease.
Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.
A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.
In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.
Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT
Deep Capillary Plexus Microaneurysms A Sign of CKD in Diabetic Retinopathy
1.
Brain cancer: a Q&A session.
2.
A healthier lifestyle after bowel screening shown to prevent bowel cancer
3.
How wildfires pose challenges to cancer care
4.
Getting ahead of head and neck cancer
5.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
1.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
2.
Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment
3.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
4.
Clinical Analysis of Prostate Cancer
5.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part IX
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation